Table 1 Demographics of study participant cohort.
|  | OLD (N = 25) | Without OLD (N = 26) | Total (N = 51) |
|---|---|---|---|
Sex | |||
 Male | 19 (76.0%) | 18 (69.2%) | 37 (72.5%) |
 Female | 6 (24.0%) | 8 (30.8%) | 14 (27.5%) |
Age | |||
 Mean (SD) | 60.0 (8.47) | 53.8 (7.30) | 56.8 (8.42) |
 Median [min, max] | 58.0 [44.0, 80.0] | 54.0 [42.0, 76.0] | 56.0 [42.0, 80.0] |
Ethnicity | |||
 Black, Non-Hispanic | 16 (64.0%) | 12 (46.2%) | 28 (54.9%) |
 White, Hispanic/Latino | 9 (36.0%) | 13 (50.0%) | 22 (43.1%) |
 Asian/pacific islander | 0 (0%) | 1 (3.8%) | 1 (2.0%) |
Smoking status | |||
 Former | 9 (36.0%) | 7 (26.9%) | 16 (31.4%) |
 Never | 3 (12.0%) | 5 (19.2%) | 8 (15.7%) |
 Yes | 13 (52.0%) | 14 (53.8%) | 27 (52.9%) |
Pack years | |||
 Mean (SD) | 31.1 (28.9) | 15.2 (13.7) | 23.0 (23.7) |
 Median [min, max] | 29.2 [0, 120] | 13.6 [0, 38.0] | 17.0 [0, 120] |
Receiving antiretroviral treatment | |||
 Yes | 23 (92.0%) | 24 (92.3%) | 47 (92.2%) |
 No | 2 (8.0%) | 2 (7.7%) | 4 (7.8%) |
FEV1-percent-predicted | |||
 Mean (SD) | 67.5 (16.1) | 104 (11.2) | 85.9 (22.8) |
 Median [min, max] | 68.2 [21.0, 90.4] | 102 [81.3, 128] | 87.1 [21.0, 128] |
FEV1 | |||
 Mean (SD) | 2.05 (0.600) | 3.25 (0.746) | 2.66 (0.905) |
 Median [min, max] | 2.00 [0.650, 3.29] | 3.08 [1.95, 4.77] | 2.59 [0.650, 4.77] |
FEV1/FVC | |||
 Mean (SD) | 0.553 (0.115) | 0.795 (0.0567) | 0.676 (0.151) |
 Median [min, max] | 0.588 [0.293, 0.679] | 0.789 [0.689, 0.905] | 0.689 [0.293, 0.905] |
DLCO-percent-predicted | |||
 Mean (SD) | 70.5 (26.5) | 76.6 (23.1) | 73.7 (24.7) |
 Median [min, max] | 57.1 [36.3, 139] | 74.5 [14.4, 117] | 73.3 [14.4, 139] |
MÂ issing | 6 (24.0%) | 5 (19.2%) | 11 (21.6%) |
Viral load | |||
 < 50 copies | 12 (48.0%) | 18 (69.2%) | 30 (58.8%) |
 > 50 copies | 1 (4.0%) | 3 (11.5%) | 4 (7.8%) |
Missing | 12 (48.0%) | 5 (19.2%) | 17 (33.3%) |